Core Viewpoint - The launch of the new journal "Nature Sensors" aims to cover the entire field of sensing technology, emphasizing its transformative impact on society and encouraging interdisciplinary collaboration to address complex challenges in various sectors [2]. Group 1: Journal Overview - "Nature Sensors" is a new addition to the Nature family, which now includes 67 journals, with 26 being review journals and 41 research journals [2]. - The journal focuses on the development of novel sensor materials and devices, as well as the design, integration, and broader applications of sensor systems [2]. - It highlights advancements in sensor design, materials, signal processing, and data analysis, aiming to connect scientific research, engineering, and industry [2]. Group 2: Topics Covered - The journal encompasses a wide range of topics including imaging sensors, sensor materials, signal processing, sensor circuits, optical sensing, quantum sensing, acoustic and ultrasonic sensing, chemical sensors, nanosenors, biosensors, wearable sensors, implantable sensors, instant diagnostics, data analysis, IoT, big data, sensor networks, structural health monitoring, environmental sensing, smart materials and structures, remote sensing, sustainability and green technology, robotic sensor integration, autonomous systems, human-computer interaction, AI-enhanced sensing, edge computing, industrial automation, predictive maintenance, supply chain and inventory management, wireless sensing, and 5G/6G sensor networks [3]. Group 3: Editorial Team - The journal is led by Dr. Olga Bubnova, who has a background in mechanical engineering and has held various editorial positions within the Nature publishing group [4][6]. - Dr. Frank Sun serves as the deputy editor, with expertise in biointerface materials and biomedical platforms [7][9].

Financial Data and Key Metrics Changes - The company reported a revenue growth of 55.4% in the last quarter, with an operating margin of 27.8% and an EPS growth of 11% [21][22][27] - The company ended the fiscal year with a billion dollars in the cardiac ablation business, aiming to double that in the near term [8][26] Business Line Data and Key Metrics Changes - The cardiac ablation solutions (CAS) business reached a billion dollars in revenue, with expectations to reach a $2 billion run rate soon [85][86] - The diabetes business has shown six consecutive quarters of double-digit growth, indicating a strong pipeline and readiness for separation [25][42] Market Data and Key Metrics Changes - The total addressable market (TAM) for hypertension therapy is significant, with 18 million patients in the U.S. potentially benefiting from the therapy, translating to $2 to $3 billion in revenue for every 1% market penetration [10][102] - The cardiac ablation market is valued at $10 billion and is growing at over 20% [7][85] Company Strategy and Development Direction - The company is focusing on innovation-driven growth across three main portfolios: cardiovascular, neuroscience, and surgery, with a strong emphasis on technology differentiation [4][5][56] - The decision to separate the diabetes business is aimed at allowing the company to focus more on higher profit areas, which are expected to accelerate growth [25][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the health of end markets driven by demographics and innovation, stating that it is a good time to be in med tech [12][13] - The company is committed to increasing R&D investment and capital allocation towards higher growth markets, with a focus on synergies across product lines [23][30] Other Important Information - The company is increasing R&D investment faster than revenue for the first time in four years, indicating a strategic shift towards innovation [23][24] - Management highlighted the importance of AI, robotics, and sensing technologies in enhancing product offerings and operational efficiency [14][18] Q&A Session Summary Question: Why is now the right time to separate the diabetes business? - Management indicated that the diabetes business is now healthy and ready to stand alone, allowing Medtronic to focus on faster growth in other areas [44][45] Question: What are the expected benefits of the diabetes separation? - The separation is expected to unlock shareholder value and allow for more focused investment in higher profit areas [26][49] Question: How does the company plan to improve gross margins? - Management discussed strategies including better pricing governance, cost reductions, and addressing mix headwinds from diabetes and CAS [63][67] Question: What is the outlook for EPS growth in fiscal 2027? - Management expects high single-digit EPS growth in fiscal 2027 following the diabetes separation [80][81]